Bristol-Myers wins US Opdivo approval three months early
This article was originally published in Scrip
Executive Summary
The US FDA granted accelerated approval for Bristol-Myers Squibb's programmed cell death-1 (PD-1) inhibitor Opdivo (nivolumab) for the treatment of advanced melanoma more than three months earlier than expected.
You may also be interested in...
US FDA Shows Relaxed Approach On Personalized Medicine In Zejula Approval
Tesaro's ovarian cancer treatment performed better in patients with BRCA mutation, but FDA did not restrict indication, leaving decision to providers.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.